EPZM - Epizyme says Boehringer terminates collaboration agreement

Epizyme (EPZM) said Boehringer Ingelheim International ((BII)) has elected to terminate a collaboration agreement between both the companies, without providing any cause for the termination, effective January 31.Under the agreement, the parties had agreed to discover, research, develop and commercialize small molecule compounds that are inhibitors of an undisclosed histone acetyltransferase ((HAT)) target and an undisclosed helicase target in indications chosen by BII.As per the pact, Epizyme granted to BII an exclusive, worldwide license to the Company’s undisclosed target inhibitors technology, and the parties had granted reciprocal licenses for each party to utilize the other party’s know-how, patents and technologies for activities. BII was solely responsible for developing and commercializing products containing compounds that inhibit the HAT target. The parties had agreed to jointly research and develop products containing compounds that inhibit the helicase target and share commercialization activities in the U.S.BII was solely responsible for commercialization of such products outside of

For further details see:

Epizyme says Boehringer terminates collaboration agreement